[This Week's IPO] Public Subscription and Bookbuilding Schedule for the Third Week of July

In the third week of July, HL Genomics will conduct its public subscription for retail investors.

<Public Subscription>

◆HL Genomics= The final offering price has been set at the upper end of the desired price band, at 21,500 won (the band was 18,500–21,500 won). A total of 2,148 domestic and overseas institutional investors participated in the demand forecast, resulting in a competition ratio of 714.5 to 1. The public subscription for retail investors will take place over two days, July 13 and 14, and the company is scheduled to be listed on the KOSDAQ market on July 24. The lead underwriter is KB Securities, with IBK Investment & Securities serving as co-manager.

HL Genomics is a specialized active pharmaceutical ingredient (API) company that produces high-quality API products based on its long-accumulated synthesis technology and GMP-based quality management capabilities. Its three main API products are pitavastatin calcium (used in hyperlipidemia treatment), S-amlodipine nicotinate (used in hypertension treatment), and bepotastine besilate (used in the treatment of allergic rhinitis).

This content was produced with the assistance of AI translation services.